A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2013

At a glance

  • Drugs Davunetide (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Sponsors Allon Therapeutics
  • Most Recent Events

    • 31 Jul 2008 Primary endpoint results presented at ADRD in July 2008
    • 28 Jul 2008 Allon Therapeutics to present AL-108 phase IIa efficacy data at ICAD 2008.
    • 12 Mar 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top